Natera

Natera, Inc. is a global leader in cell-free DNA (cfDNA) testing, focusing on oncology, women’s health, and organ health. Founded in 2004, the company operates CLIA-certified and CAP-accredited laboratories in Austin, Texas, and San Carlos, California. Natera aims to integrate personalized genetic testing into standard healthcare, enabling early and targeted interventions for better patient outcomes.The company offers several key products, including Signatera™, a ctDNA assay for detecting molecular residual disease and monitoring recurrence in cancers; Panorama™, a non-invasive prenatal test for identifying chromosomal abnormalities; and Prospera™, a test for monitoring kidney transplant rejection. Natera employs advanced molecular biology, bioinformatics, and AI in its proprietary cfDNA platform, ensuring high accuracy through rigorous validation and compliance with industry standards.Natera serves healthcare providers, researchers, and patients worldwide, conducting over 70,000 annual support sessions. The company is committed to expanding its test portfolio through large-scale trials and partnerships, with a focus on precision medicine and early disease detection.